Bolt Biotherapeutics (BOLT) Cash from Investing Activities (2020 - 2026)

Bolt Biotherapeutics has reported Cash from Investing Activities for 7 years, with the latest figure at $7.9 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 45.55% year-over-year to $7.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37.7 million (down 39.16% YoY) and the FY2025 annual result came in at $44.3 million, down 23.05% from the prior year.
• Cash from Investing Activities grew to $7.9 million in Q1 2026 per BOLT's latest filing, from $1.1 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $40.8 million in Q1 2022 and troughed at -$868000.0 in Q2 2022.
• A 5-year average of $14.0 million and a median of $13.6 million in 2023 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2023 and 2025: Cash from Investing Activities surged 1664.52% in 2023, then sank 91.22% in 2025.
• Over 5 years, Cash from Investing Activities stood at $16.4 million in 2022, then slipped by 3.81% to $15.8 million in 2023, then decreased by 22.63% to $12.2 million in 2024, then tumbled by 91.22% to $1.1 million in 2025, then surged by 637.71% to $7.9 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $7.9 million, $1.1 million, and $17.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.